AKOUSTIS TECHNOLOGIES, INC. Stock Prediction
AI-powered sentiment analysis and prediction trends for AKTS, updated each market day.
AKTS AI Sentiment
AI predicts AKOUSTIS TECHNOLOGIES, INC. stock is likely to decrease over the next 10 market days.
Prediction date: Dec. 18, 2024
Subscribers see precise scores, buy/sell targets, and full analytics.
About AKOUSTIS TECHNOLOGIES, INC.
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
Sector
Exchange
Market Cap
$976,726,955
Cap Tier
Employees
79
Headquarters
BOSTON, MA
Listed Since
Jan. 9, 2026
Website
AKTS Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
AKTS Volatility
AKOUSTIS TECHNOLOGIES, INC. has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
